<DOC>
	<DOCNO>NCT00928343</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single ascending ( SAD ) subcutaneous single oral dose GLPG0187 compare placebo . Also , pharmacokinetics ( PK ) pharmacodynamics ( PD ) GLPG0187 single subcutaneous oral administration evaluate , , applicable , maximum tolerate dose determine .</brief_summary>
	<brief_title>First-in-Human Single Ascending Subcutaneous ( s.c. ) Dose Single Oral Dose GLPG0187</brief_title>
	<detailed_description />
	<criteria>healthy male , age 1850 year BMI 1830 kg/mÂ² , inclusive significantly abnormal platelet function coagulopathy smoke drug alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>